AR046762A1 - Hormonas de administracion transdermica que no necesitan potenciadores de penetracion - Google Patents
Hormonas de administracion transdermica que no necesitan potenciadores de penetracionInfo
- Publication number
- AR046762A1 AR046762A1 ARP040104605A ARP040104605A AR046762A1 AR 046762 A1 AR046762 A1 AR 046762A1 AR P040104605 A ARP040104605 A AR P040104605A AR P040104605 A ARP040104605 A AR P040104605A AR 046762 A1 AR046762 A1 AR 046762A1
- Authority
- AR
- Argentina
- Prior art keywords
- hormones
- patch
- potentiators
- transdermal administration
- need
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles en plasma de al menos 1,0 ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeacion en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que consiguen durante todo un periodo de al menos 1 semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semana. Composición, kit, método de tratamiento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078881 | 2003-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046762A1 true AR046762A1 (es) | 2005-12-21 |
Family
ID=34924031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104605A AR046762A1 (es) | 2003-12-12 | 2004-12-10 | Hormonas de administracion transdermica que no necesitan potenciadores de penetracion |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP2138169B1 (es) |
| CN (1) | CN101843603B (es) |
| AR (1) | AR046762A1 (es) |
| AT (1) | ATE457168T1 (es) |
| CR (1) | CR8465A (es) |
| CY (2) | CY1110637T1 (es) |
| DE (1) | DE602004025444D1 (es) |
| DK (2) | DK2138169T3 (es) |
| ES (2) | ES2340925T3 (es) |
| GT (1) | GT200400262A (es) |
| HK (2) | HK1074801A1 (es) |
| HN (1) | HN2004000526A (es) |
| HR (2) | HRP20100254T1 (es) |
| JO (1) | JO2606B1 (es) |
| ME (1) | ME01069B (es) |
| MY (2) | MY144053A (es) |
| PE (1) | PE20051035A1 (es) |
| PL (2) | PL2138169T3 (es) |
| PT (2) | PT2138169E (es) |
| RS (2) | RS53182B (es) |
| SI (2) | SI1541137T1 (es) |
| SV (1) | SV2006001970A (es) |
| TW (1) | TWI257299B (es) |
| UA (1) | UA89766C2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1594483E (pt) | 2003-02-21 | 2006-12-29 | Schering Ag | Penso transdérmico estável aos uv |
| US8668925B2 (en) | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| US8962013B2 (en) | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
| DE102005050729A1 (de) * | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
| ES2795455T3 (es) | 2008-10-08 | 2020-11-23 | Agile Therapeutics Inc | Suministro transdérmico |
| WO2010042607A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc | Transdermal delivery |
| WO2010042610A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
| EP2410859A4 (en) | 2009-03-27 | 2013-03-13 | Agile Therapeutics Inc | TRANSDERMAL ADMINISTRATION |
| AU2015203180B2 (en) * | 2010-09-06 | 2016-06-30 | Bayer Intellectual Property Gmbh | Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) |
| HUE031326T2 (hu) | 2010-09-06 | 2017-07-28 | Bayer Ip Gmbh | Alacsony dózisú transzdermális tapaszok magas hatóanyagleadással |
| DE102010040299A1 (de) * | 2010-09-06 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
| MX2014008693A (es) * | 2012-01-27 | 2014-08-27 | Agile Therapeutics Inc | Administracion transdermica de hormonas. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4081537A (en) | 1975-10-10 | 1978-03-28 | Schering Aktiengesellschaft | Δ15 -Steroids and pharmaceutical compositions thereof |
| EP0394429B1 (de) * | 1988-10-27 | 1996-01-10 | Schering Aktiengesellschaft | Mittel zur transdermalen applikation enthaltend gestoden |
| US5512292A (en) * | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
| MX9101787A (es) * | 1990-10-29 | 1992-06-05 | Alza Corp | Formulaciones,metodos y dispositivos anticonceptivos transdermicos |
| DE4336557C2 (de) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
| DE4329242A1 (de) | 1993-08-26 | 1995-03-02 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Gestodenester |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
| DE19906152B4 (de) * | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| ES2338860T3 (es) | 1999-11-24 | 2010-05-13 | Agile Therapeutics, Inc. | Sistema y procedimiento de administracion de anticonceptivos transdermica mejorado. |
| DE10053375C1 (de) * | 2000-10-27 | 2002-01-24 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen |
| WO2002045701A2 (en) * | 2000-12-05 | 2002-06-13 | Noven Pharmaceuticals, Inc. | Crystallization inhibition of drugs in transdermal drug delivery systems |
-
2004
- 2004-10-12 UA UAA200607580A patent/UA89766C2/ru unknown
- 2004-11-18 JO JO2004159A patent/JO2606B1/en active
- 2004-12-10 DK DK09173898.9T patent/DK2138169T3/da active
- 2004-12-10 HN HN2004000526A patent/HN2004000526A/es unknown
- 2004-12-10 RS YU20140050A patent/RS53182B/en unknown
- 2004-12-10 ES ES04078365T patent/ES2340925T3/es active Active
- 2004-12-10 PT PT91738989T patent/PT2138169E/pt unknown
- 2004-12-10 PL PL09173898T patent/PL2138169T3/pl unknown
- 2004-12-10 PL PL04078365T patent/PL1541137T3/pl unknown
- 2004-12-10 TW TW093138443A patent/TWI257299B/zh not_active IP Right Cessation
- 2004-12-10 CN CN2010101564978A patent/CN101843603B/zh active Active
- 2004-12-10 MY MYPI20045107A patent/MY144053A/en unknown
- 2004-12-10 PT PT04078365T patent/PT1541137E/pt unknown
- 2004-12-10 RS RSP-2010/0202A patent/RS51260B/sr unknown
- 2004-12-10 SI SI200431404T patent/SI1541137T1/sl unknown
- 2004-12-10 AT AT04078365T patent/ATE457168T1/de active
- 2004-12-10 DE DE602004025444T patent/DE602004025444D1/de active Active
- 2004-12-10 PE PE2004001230A patent/PE20051035A1/es active IP Right Grant
- 2004-12-10 SV SV2004001970A patent/SV2006001970A/es not_active Application Discontinuation
- 2004-12-10 SI SI200432127T patent/SI2138169T1/sl unknown
- 2004-12-10 EP EP09173898.9A patent/EP2138169B1/en active Active
- 2004-12-10 ME MEP-2010-79A patent/ME01069B/me unknown
- 2004-12-10 DK DK04078365.6T patent/DK1541137T3/da active
- 2004-12-10 GT GT200400262A patent/GT200400262A/es unknown
- 2004-12-10 EP EP04078365A patent/EP1541137B1/en active Active
- 2004-12-10 AR ARP040104605A patent/AR046762A1/es not_active Application Discontinuation
- 2004-12-10 ES ES09173898.9T patent/ES2445690T3/es active Active
-
2005
- 2005-10-07 HK HK05108895.4A patent/HK1074801A1/xx not_active IP Right Cessation
-
2006
- 2006-06-20 CR CR8465A patent/CR8465A/es unknown
-
2010
- 2010-01-12 HK HK10100292.3A patent/HK1132682A1/xx not_active IP Right Cessation
- 2010-03-31 MY MYPI2010001448 patent/MY152750A/en unknown
- 2010-05-04 HR HR20100254T patent/HRP20100254T1/hr unknown
- 2010-05-07 CY CY20101100401T patent/CY1110637T1/el unknown
-
2014
- 2014-01-24 HR HRP20140077TT patent/HRP20140077T1/hr unknown
- 2014-02-06 CY CY20141100099T patent/CY1115064T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR8465A (es) | Hormonas de administracion transdermica que no necesitan potenciadores de penetracion | |
| CU20100143A7 (es) | Hormonas de administración transdérmica que no necesitan potenciadores de penetración | |
| DK0836506T4 (da) | Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen | |
| NO993520L (no) | Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon | |
| BR0107535A (pt) | Uso de carotenóides e forma de dosagem unitária destes | |
| BR0312007A (pt) | Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas | |
| AR048878A1 (es) | Composiciones topicas de metadona y metodos para usarlas | |
| AR048722A1 (es) | Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos | |
| MX2022008277A (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| AR021459A1 (es) | PARCHE QUE CONTIENE ESTRADIOL PARA LA APLICACIoN PERCUTÁNEA DE HORMONAS. | |
| DE60318447D1 (de) | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung | |
| PE20070119A1 (es) | Nuevos regimenes para dispositivos de suministro controlado de farmacos para la anticoncepcion | |
| AR036970A1 (es) | Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion | |
| UY28668A1 (es) | Hormonas de administración transdérmica que no necesitan potenciadores de penetración | |
| JO2492B1 (en) | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients | |
| CU23649B7 (es) | Hormonas de administración transdérmica que no necesitan potenciadores de penetración | |
| ATE269063T1 (de) | Formulierungen zur transdermalen verabreichung von fenoldopam | |
| SE0001428D0 (sv) | Treatment of hypertrophic cardiomyopathy with a substance that decreases the level of igf-i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |